Indication

Target/marker/pathway

Summary

Licensing status

Publication and contact
information

Cancer

Breast cancer

SWI/SNF-related matrix-associated actin-dependent regulator of chromatin subfamily c member 1
(SMARCC1; BAF155); coactivator-associated arginine methyltransferase 1 (CARM1)

In vitro and mouse studies suggest inhibiting BAF155 methylation by CARM1 could help treat metastatic breast cancer. In breast cancer cells, BAF155 was identified as a substrate of the CARM1 methyltransferase. In the cells, BAF155 knockout decreased cell growth and migration, which was restored by expression of wild-type BAF155 but not of a variant with a mutated methylation site. In tissue samples from breast cancer patients, lack of BAF155 methylation increased recurrence-free survival compared with the presence of BAF155 methylation. In mouse xenograft models of metastatic breast cancer, expression of a methylation-resistant BAF155 mutant prevented tumor growth in the lungs. Next steps include identifying inhibitors of CARM1-mediated BAF155 methylation.

SciBX 7(5); doi:10.1038/scibx.2014.138
Published online Feb. 6, 2014

Unpatented; licensing status not applicable

Wang, L. et al. Cancer Cell; published online Jan. 13, 2014;
doi:10.1016/j.ccr.2013.12.007
Contact: Wei Xu, University of Wisconsin-Madison, Madison, Wis.
e-mail:
wxu@oncology.wisc.edu